Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1149378#aggregation> ?p ?o. }
Showing items 1 to 47 of
47
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B381440.
- aggregation creator B381441.
- aggregation creator B381442.
- aggregation creator B381443.
- aggregation creator B381444.
- aggregation creator B381445.
- aggregation creator B381446.
- aggregation creator B381447.
- aggregation creator B381448.
- aggregation creator B381449.
- aggregation creator B381450.
- aggregation creator B381451.
- aggregation creator B381452.
- aggregation creator B381453.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2010".
- aggregation format "application/pdf".
- aggregation hasFormat 1149378.bibtex.
- aggregation hasFormat 1149378.csv.
- aggregation hasFormat 1149378.dc.
- aggregation hasFormat 1149378.didl.
- aggregation hasFormat 1149378.doc.
- aggregation hasFormat 1149378.json.
- aggregation hasFormat 1149378.mets.
- aggregation hasFormat 1149378.mods.
- aggregation hasFormat 1149378.rdf.
- aggregation hasFormat 1149378.ris.
- aggregation hasFormat 1149378.txt.
- aggregation hasFormat 1149378.xls.
- aggregation hasFormat 1149378.yaml.
- aggregation isPartOf urn:issn:0140-6736.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial".
- aggregation abstract "Background Vascular Ehlers-Danlos syndrome is a rare severe disease that causes arterial dissections and ruptures that can lead to early death. No preventive treatment has yet been validated. Our aim was to assess the ability of celiprolol, a beta(1)-adrenoceptor antagonist with a beta(2)-adrenoceptor agonist action, to prevent arterial dissections and ruptures in vascular Ehlers-Danlos syndrome. Methods Our study was a multicentre, randomised, open trial with blinded assessment of clinical events in eight centres in France and one in Belgium. Patients with clinical vascular Ehlers-Danlos syndrome were randomly assigned to 5 years of treatment with celiprolol or to no treatment. Randomisation was done from a centralised, previously established list of sealed envelopes with stratification by patients' age (<= 32 years or >32 years). 33 patients were positive for mutation of collagen 3A1 (COL3A1). Celiprolol was uptitrated every 6 months by steps of 100 mg to a maximum of 400 mg twice daily. The primary endpoints were arterial events (rupture or dissection, fatal or not). This study is registered with ClinicalTrials.gov, number NCT00190411. Findings 53 patients were randomly assigned to celiprolol (25 patients) or control groups (28). Mean duration of follow-up was 47 (SD 5) months, with the trial stopped early for treatment benefit. The primary endpoints were reached by five (20%) in the celiprolol group and by 14 (50%) controls (hazard ratio [HR] 0.36; 95% CI 0.15-0.88; p=0.040). Adverse events were severe fatigue in one patient after starting 100 mg celiprolol and mild fatigue in two patients related to dose uptitration. Interpretation We suggest that celiprolol might be the treatment of choice for physicians aiming to prevent major complications in patients with vascular Ehlers-Danlos syndrome. Whether patients with similar clinical presentations and no mutation are also protected remains to be established.".
- aggregation authorList BK689083.
- aggregation endPage "1484".
- aggregation issue "9751".
- aggregation startPage "1476".
- aggregation volume "376".
- aggregation aggregates 1149432.
- aggregation isDescribedBy 1149378.
- aggregation similarTo S0140-6736(10)60960-9.
- aggregation similarTo LU-1149378.